Cell Death and Clonal Survival in Myelodysplastic Syndr*
Cell Death and Clonal Survival in Myelodysplastic Syndr*
批准号:
7487816
负责人:
H. JOACHIM DEEG
金额:
$41.01万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-15 至 2010-08-31
关键词:
AffectAgeAgingApoptosisApoptoticCategoriesCell DeathCell LineCell SurvivalCell TransplantsCellsCessation of lifeChronicClinicalClonal ExpansionComplexCountDataDefective spinal cord developmentDiseaseDisease ProgressionDysmyelopoietic SyndromesElevationEventFrequenciesFunctional disorderGene ExpressionGeneticHematopoiesisHematopoieticHematopoietic stem cellsHumanImmunodeficient MouseIn VitroIncidenceIndividualInflammatoryInterventionKaryotypeMarrowMediatingModelingModificationMolecular TargetMononuclearMusMyeloid CellsNF-kappa BPatientsPatternPlayPopulationProcessProtein OverexpressionQuality of lifeRegulationRoleSignal PathwaySignal TransductionStromal CellsSystemTechniquesTestingTransplantationTumor Necrosis Factor-alphaTumor Necrosis Factorscell stromacytokinehuman TNF proteinimprovedin vitro Assayin vivoin vivo Modelmyeloblastnovelnovel therapeuticsprevent
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The Myelodysplastic Syndrome (MDS) is predominantly a disease of older age, and with the aging of the population, an increase in cases is expected. Our proposal is aimed at improving our understanding of the pathophysiology of MDS, and to identify cellular or molecular targets suitable for novel treatment strategies. MDS is a clonal disorder of hematopoietic stem cells; however, there is evidence that factors in the microenvironment contribute to the propagation of the disease. Thus, we propose to characterize interactions between the marrow microenvironment and hematopoietic precursors and identify signaling pathways that determine programmed cell death (apoptosis) and clonal survival. Specifically, we will 1) define stroma-dependent activities that affect survival/expansion of clonal and non-clonal hematopoietic precursors from MDS marrow. In an in vitro system using myeloid cell lines and primary MDS cells, we will characterize the functional relevance of tumor necrosis factor (TNF)alpha-induced alterations in gene expression in stroma for the support of clonal or non-clonal hematopoietic precursors (TNFalpha is upregulated in MDS). In a xenogeneic in vivo model we will determine the role of human stroma for the survival of MDS-derived clones transplanted into mice. We will 2) characterize apoptotic and proliferative events in MDS marrow and correlate these with disease progression. We will define interactions of TNFalpha-initiated signals that control apoptosis and proliferation, in particular, the roles of NFkappaB and the anti-apoptotic molecule, FLIP. Preliminary in vitro data show that overexpression of FLIP enhances cell survival. We will now determine in vivo whether genetic modification of FLIP expression in MDS cells transplanted in immunodeficient mice affects survival and allows for expansion of the clone. The techniques involved in pursuit of our objectives include in vitro assays of hematopoiesis, apoptosis, and proliferation in in vitro culture systems. The relevance of in vitro findings will be validated in vivo in a xenogeneic transplant model of cell lines and primary MDS cells in immunodeficient mice in which propagation of normal and clonal cells will be characterized. By using interventions that block relevant signals or by genetically modifying molecules that play pivotal roles, we will identify potential targets for novel therapeutic strategies. The human population is aging, and the incidence of MDS increases with age. Novel treatment approaches are needed that are tolerated by older individuals and, hopefully, will not interfere with their quality of life. To achieve these objectives, we must better understand the underlying mechanisms of MDS and thereby identify ways by which the disease process can be arrested, progression prevented, and the disease hopefully be cured.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
MDS 中造血和细胞凋亡的控制:不仅仅是抛硬币。
DOI:
10.1016/j.leukres.2007.01.010
发表时间:
2007
期刊:
Leukemia research
影响因子:
2.7
作者:
[Mhyre,AndrewJ, Deeg,HJoachim]
通讯作者:
Deeg,HJoachim
Hematopoietic Cell Transplantation and Iron Overload
-
批准号:7888104
-
项目类别:
-
资助金额:$46.15万
-
财政年份:2010
-
负责人:H. JOACHIM DEEG
-
依托单位:
Hematopoietic Cell Transplantation and Iron Overload
-
批准号:8235938
-
项目类别:
-
资助金额:$43.81万
-
财政年份:2010
-
负责人:H. JOACHIM DEEG
-
依托单位:
Hematopoietic Cell Transplantation and Iron Overload
-
批准号:8055465
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2010
-
负责人:H. JOACHIM DEEG
-
依托单位:
Hematopoietic Cell Transplantation and Iron Overload
-
批准号:8434139
-
项目类别:
-
资助金额:$41.71万
-
财政年份:2010
-
负责人:H. JOACHIM DEEG
-
依托单位:
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
-
批准号:7478450
-
项目类别:
-
资助金额:$16.69万
-
财政年份:2007
-
负责人:H. JOACHIM DEEG
-
依托单位:
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
-
批准号:7304858
-
项目类别:
-
资助金额:$16.22万
-
财政年份:2006
-
负责人:H. JOACHIM DEEG
-
依托单位:
Cell Death and Clonal Survival in Myelodysplastic Syndr*
-
批准号:7278677
-
项目类别:
-
资助金额:$41.01万
-
财政年份:2005
-
负责人:H. JOACHIM DEEG
-
依托单位:
WT1 Expression in Patients with MDS Treated with ATG an*
-
批准号:7056452
-
项目类别:
-
资助金额:$27.64万
-
财政年份:2005
-
负责人:H. JOACHIM DEEG
-
依托单位:
WT1 Expression in Patients with MDS Treated with ATG an*
-
批准号:7230026
-
项目类别:
-
资助金额:$26.84万
-
财政年份:2005
-
负责人:H. JOACHIM DEEG
-
依托单位:
Cell Death and Clonal Survival in Myelodysplastic Syndr*
-
批准号:7123465
-
项目类别:
-
资助金额:$42.23万
-
财政年份:2005
-
负责人:H. JOACHIM DEEG
-
依托单位:
Cell Death and Clonal Survival in Myelodysplastic Syndr*
-
批准号:7022676
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2005
-
负责人:H. JOACHIM DEEG
-
依托单位:
TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS
-
批准号:6784817
-
项目类别:
-
资助金额:$41.66万
-
财政年份:2003
-
负责人:H. JOACHIM DEEG
-
依托单位:
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
-
批准号:6191363
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:H. JOACHIM DEEG
-
依托单位:
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
-
批准号:6514716
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:H. JOACHIM DEEG
-
依托单位:
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
-
批准号:6378111
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:H. JOACHIM DEEG
-
依托单位:
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
-
批准号:6633823
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:H. JOACHIM DEEG
-
依托单位:
CANCER FOLLOWING BONE MARROW TRANSPLANTATION
-
批准号:6294374
-
项目类别:
-
资助金额:$0.48万
-
财政年份:1995
-
负责人:H. JOACHIM DEEG
-
依托单位:
INTERNATIONAL WORKSHOP ON BONE MARROW FAILURE
-
批准号:2232248
-
项目类别:
-
资助金额:$2.0万
-
财政年份:1995
-
负责人:H. JOACHIM DEEG
-
依托单位:
CANCER FOLLOWING BONE MARROW TRANSPLANTATION
-
批准号:2879231
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1995
-
负责人:H. JOACHIM DEEG
-
依托单位:
CANCER FOLLOWING BONE MARROW TRANSPLANTATION
-
批准号:2600923
-
项目类别:
-
资助金额:$11.22万
-
财政年份:1995
-
负责人:H. JOACHIM DEEG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: